RBC Analysts See Caution in Big Pharma Stocks During Earnings Season
RBC Capital Markets analysts say investors appear increasingly cautious on big pharma stocks as third-quarter earnings unfold. They cite a negative reaction to Johnson & Johnson’s solid results last week as a sign of heightened vulnerability.
Story updates
07:29:19 AM UTC
SquawkNews
Germany's austerity measures might loom over big pharmaceutical companies when they report third-quarter results over the coming weeks, RBC Capital Markets analysts say in a research note. Johnson & Johnson's results last week showed German price declines weighed on sales of the U.S. drugmaker's Da…